What is Rapacan (Sirolimus) used for?

Rapacan (Sirolimus) is an immunosuppressant used to prevent transplant rejection (in adult patients with low to moderate immunological risk after kidney transplantation in combination with glucocorticosteroids and cyclosporine).

How should I use Rapacan (Sirolimus)?

It is recommended to prescribe Rapacan (Sirolimus) in combination with corticosteroids and cyclosporine for 2-3 months. Supportive therapy, if necessary, can be continued in combination with corticosteroids without cyclosporine.

Always follow your doctor`s instructions when using Rapacan (Sirolimus) to get the safest and most effective results from treatment.

General recommendations for initial therapy (within 2-3 months after transplantation): in the usual regimen of administration - within 48 hours after transplantation, a saturating dose of 6 mg is prescribed once, followed by a maintenance dose of 2 mg/day.

What are the side effects of Rapacan (Sirolimus)?

The use of Rapacan (Sirolimus) may cause side effects in some patients including:

• lymphocele;
• violation of wound healing;
• swelling;
• the development or activation of fungal, viral and bacterial infections (including those caused by mycobacteria and the Epstein-Barr virus).

It should be noted that during therapy, most patients simultaneously received cyclosporine and corticosteroids (side effects relate to the combination of these drugs).

Contact your doctor immediately if you experience any serious or worrying symptoms.

Please Note

There are no data on the use of Rapacan (Sirolimus) in pregnant women. During pregnancy, Rapacan (Sirolimus) should be used only in cases where the intended benefits to the mother outweigh the possible risk to the fetus.

Effective contraception must be started before treatment with Rapacan (Sirolimus) and continued during the treatment period, as well as within 12 weeks after its completion.

It is not known whether sirolimus with breast milk is excreted in humans. Given the potential risk to the baby, breastfeeding should be discontinued during Rapacan (Sirolimus) treatment.

Due to insufficient data on the safety and efficacy of the use of this medicinal product in this age group, it is not recommended for children (under 18 years of age).